Literature DB >> 21694534

Immunophenotyping of peripheral eosinophils demonstrates activation in eosinophilic esophagitis.

Tammie Nguyen1, Yael Gernez, Judy Fuentebella, Anup Patel, Rabindra Tirouvanziam, Neha Reshamwala, Dorsey Bass, William E Berquist, Kenneth L Cox, John A Kerner, Kari C Nadeau.   

Abstract

BACKGROUND AND AIM: Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder characterized by upper gastrointestinal symptoms and the presence of high numbers of eosinophils in the esophagus. Although eosinophils in the esophagus have been found to be activated in subjects with EoE, detailed studies of intracellular signaling pathways involved in the mechanism of activation of eosinophils in EoE have heretofore been limited. The aim of the study was to assess whether any surface molecules or transcription factors are activated in peripheral eosinophils in subjects with EoE.
METHODS: Eosinophils and CD3+ lymphocytes were identified directly from 50 μL of whole blood of EoE and control subjects. Using Hi-FACS, levels of surface activation markers, including CD66b, and intracellular phosphoepitopes, including phosphorylated forms of signal transducer and activator of transcription (phospho-STAT) 1 and 6, were measured within each cell subset.
RESULTS: Levels of surface CD66b as well as levels of intracellular phospho-STAT1 and phospho-STAT6 in peripheral blood eosinophils were significantly higher for untreated subjects with EoE vs healthy controls (P < 0.05). Levels of phospho-STAT1 and phospho-STAT6 in peripheral blood eosinophils were lower in subjects with EoE on therapy versus untreated subjects with EoE (P < 0.05).
CONCLUSIONS: Levels of phospho-STAT1 and phospho-STAT6, transcription factors involved in inflammatory processes, were both significantly higher in peripheral eosinophils from untreated (ie, newly diagnosed) subjects with EoE versus subjects with EoE on therapy, healthy controls. Blood-based measurements of CD66b and phospho-STAT levels in peripheral eosinophils may be beneficial for identifying EoE.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21694534      PMCID: PMC4169142          DOI: 10.1097/MPG.0b013e318212647a

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  35 in total

Review 1.  Stats: multifaceted regulators of transcription.

Authors:  Melissa M Brierley; Eleanor N Fish
Journal:  J Interferon Cytokine Res       Date:  2005-12       Impact factor: 2.607

2.  Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.

Authors:  Miguel L Stein; Margaret H Collins; Joyce M Villanueva; Jonathan P Kushner; Philip E Putnam; Bridget K Buckmeier; Alexandra H Filipovich; Amal H Assa'ad; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2006-11-07       Impact factor: 10.793

3.  Increased number of regulatory T cells in children with eosinophilic esophagitis.

Authors:  Judy Fuentebella; Anup Patel; Tammie Nguyen; Bharati Sanjanwala; William Berquist; John A Kerner; Dorsey Bass; Kenneth Cox; Melissa Hurwitz; Jennifer Huang; Christine Nguyen; J Antonio Quiros; Kari Nadeau
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-09       Impact factor: 2.839

Review 4.  Mechanism of eosinophilic esophagitis.

Authors:  Anil Mishra
Journal:  Immunol Allergy Clin North Am       Date:  2009-02       Impact factor: 3.479

5.  Treatment with topical steroids downregulates IL-5, eotaxin-1/CCL11, and eotaxin-3/CCL26 gene expression in eosinophilic esophagitis.

Authors:  Alfredo J Lucendo; Livia De Rezende; Carmen Comas; Teresa Caballero; Teresa Bellón
Journal:  Am J Gastroenterol       Date:  2008-09       Impact factor: 10.864

6.  Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children.

Authors:  Seema S Aceves; John F Bastian; Robert O Newbury; Ranjan Dohil
Journal:  Am J Gastroenterol       Date:  2007-06-20       Impact factor: 10.864

Review 7.  Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense.

Authors:  Shen-Ying Zhang; Stéphanie Boisson-Dupuis; Ariane Chapgier; Kun Yang; Jacinta Bustamante; Anne Puel; Capucine Picard; Laurent Abel; Emmanuelle Jouanguy; Jean-Laurent Casanova
Journal:  Immunol Rev       Date:  2008-12       Impact factor: 12.988

8.  CD66b regulates adhesion and activation of human eosinophils.

Authors:  Juhan Yoon; Akihiko Terada; Hirohito Kita
Journal:  J Immunol       Date:  2007-12-15       Impact factor: 5.422

9.  Differential regulation of chemokine expression by Th1 and Th2 cytokines and mechanisms of eotaxin/CCL-11 expression in human airway smooth muscle cells.

Authors:  Miho Odaka; Satoshi Matsukura; Hideki Kuga; Fumio Kokubu; Tsuyoshi Kasama; Masatsugu Kurokawa; Mio Kawaguchi; Koushi Ieki; Shintaro Suzuki; Shin Watanabe; Tetsuya Homma; Hiroko Takeuchi; Kyoko Nohtomi; Robert P Schleimer; Mitsuru Adachi
Journal:  Int Arch Allergy Immunol       Date:  2007-05-01       Impact factor: 2.749

10.  Interleukin-13 directly promotes oesophagus production of CCL11 and CCL24 and the migration of eosinophils.

Authors:  C V Neilsen; P J Bryce
Journal:  Clin Exp Allergy       Date:  2009-12-16       Impact factor: 5.018

View more
  9 in total

Review 1.  Non- and semi-invasive methods of monitoring eosinophilic esophagitis.

Authors:  Calies Menard-Katcher; Glenn T Furuta
Journal:  Dig Dis       Date:  2014-02-28       Impact factor: 2.404

Review 2.  Models and Tools for Investigating Eosinophilic Esophagitis at the Bench.

Authors:  Amiko M Uchida; Gabrielle Ro; John J Garber; Kathryn A Peterson; June L Round
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

3.  Minimally invasive biomarker studies in eosinophilic esophagitis: A systematic review.

Authors:  Brittany T Hines; Matthew A Rank; Benjamin L Wright; Lisa A Marks; John B Hagan; Alex Straumann; Matthew Greenhawt; Evan S Dellon
Journal:  Ann Allergy Asthma Immunol       Date:  2018-05-16       Impact factor: 6.347

4.  A pilot study of omalizumab in eosinophilic esophagitis.

Authors:  Denise Loizou; Benjamin Enav; Edina Komlodi-Pasztor; Pamela Hider; Julie Kim-Chang; Laura Noonan; Tabitha Taber; Suhasini Kaushal; Renuka Limgala; Margaret Brown; Raavi Gupta; Nader Balba; Ozlem Goker-Alpan; Amer Khojah; Oral Alpan
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

Review 5.  Clinical Applications of the Eosinophilic Esophagitis Diagnostic Panel.

Authors:  Ting Wen; Marc E Rothenberg
Journal:  Front Med (Lausanne)       Date:  2017-07-14

Review 6.  Tissue Remodeling in Chronic Eosinophilic Esophageal Inflammation: Parallels in Asthma and Therapeutic Perspectives.

Authors:  Quan M Nhu; Seema S Aceves
Journal:  Front Med (Lausanne)       Date:  2017-08-07

7.  Case Report: Eosinophilic Esophagitis in a Patient With a Novel STAT1 Gain-of-Function Pathogenic Variant.

Authors:  Ori Scott; Nigel Sharfe; Harjit Dadi; Linda Vong; Jenny Garkaby; Laura Abrego Fuentes; Jessica Willett Pachul; Sandra Nelles; Amit Nahum; Chaim M Roifman
Journal:  Front Immunol       Date:  2022-01-20       Impact factor: 7.561

Review 8.  Non-invasive biomarkers of eosinophilic esophagitis.

Authors:  Martina Votto; Maria De Filippo; Riccardo Castagnoli; Francesco Delle Cave; Francesca Giffoni; Viola Santi; Marta Vergani; Carlo Caffarelli; Mara De Amici; Gian Luigi Marseglia; Amelia Licari
Journal:  Acta Biomed       Date:  2021-11-29

Review 9.  Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases.

Authors:  Dean D Metcalfe; Ruby Pawankar; Steven J Ackerman; Cem Akin; Frederic Clayton; Franco H Falcone; Gerald J Gleich; Anne-Marie Irani; Mats W Johansson; Amy D Klion; Kristin M Leiferman; Francesca Levi-Schaffer; Gunnar Nilsson; Yoshimichi Okayama; Calman Prussin; John T Schroeder; Lawrence B Schwartz; Hans-Uwe Simon; Andrew F Walls; Massimo Triggiani
Journal:  World Allergy Organ J       Date:  2016-02-11       Impact factor: 4.084

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.